EntryPoint Capital LLC Buys Shares of 12,225 Janux Therapeutics, Inc. (NASDAQ:JANX)

EntryPoint Capital LLC purchased a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) during the 4th quarter, HoldingsChannel reports. The firm purchased 12,225 shares of the company’s stock, valued at approximately $655,000.

A number of other hedge funds and other institutional investors have also modified their holdings of JANX. FMR LLC raised its holdings in Janux Therapeutics by 0.6% during the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock valued at $355,475,000 after buying an additional 47,075 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Janux Therapeutics by 40.0% in the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after buying an additional 721,563 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Janux Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company’s stock worth $114,379,000 after buying an additional 288,402 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Janux Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock worth $30,107,000 after buying an additional 38,490 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in Janux Therapeutics by 190.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after buying an additional 259,445 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $31.74 on Tuesday. The company has a 50-day moving average of $36.62 and a 200-day moving average of $46.38. Janux Therapeutics, Inc. has a 52 week low of $28.92 and a 52 week high of $71.71. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -27.13 and a beta of 3.23.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Stifel Nicolaus upped their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. Wedbush reissued an “outperform” rating and issued a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, Leerink Partners boosted their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $92.44.

Insider Buying and Selling

In other news, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the transaction, the insider now owns 82,139 shares in the company, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO David Alan Campbell sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief executive officer now owns 293,054 shares in the company, valued at approximately $17,583,240. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 25,002 shares of company stock worth $1,279,953 in the last 90 days. 29.40% of the stock is owned by company insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.